290 related articles for article (PubMed ID: 26481215)
1. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
Takagi Y; Hosomi Y; Oshita F; Okamoto H; Seki N; Minato K; Aono H; Yamada K; Okuma Y; Hida N; Sakamoto T; Miura Y; Yomota M; Satoh A; Kunitoh H; Sakamaki K; Shibuya M; Watanabe K
BMC Cancer; 2015 Oct; 15():740. PubMed ID: 26481215
[TBL] [Abstract][Full Text] [Related]
2. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
Piperdi B; Walsh WV; Bradley K; Zhou Z; Bathini V; Hanrahan-Boshes M; Hutchinson L; Perez-Soler R
J Thorac Oncol; 2012 Jun; 7(6):1032-40. PubMed ID: 22534815
[TBL] [Abstract][Full Text] [Related]
3. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.
Cascone T; Gold KA; Swisher SG; Liu DD; Fossella FV; Sepesi B; Pataer A; Weissferdt A; Kalhor N; Vaporciyan AA; Hofstetter WL; Wistuba II; Heymach JV; Kim ES; William WN
Ann Thorac Surg; 2018 Feb; 105(2):418-424. PubMed ID: 29217088
[TBL] [Abstract][Full Text] [Related]
4. An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.
Yamamoto N; Kenmotsu H; Goto K; Takeda K; Kato T; Takeda M; Horinouchi H; Saito I; Sarashina A; Tanaka T; Morsli N; Nakagawa K
Cancer Chemother Pharmacol; 2018 Oct; 82(4):685-694. PubMed ID: 30073583
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2'-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles.
Peng L; Feng L; Yuan H; Benhabbour SR; Mumper RJ
Nanomedicine; 2014 Oct; 10(7):1497-506. PubMed ID: 24709328
[TBL] [Abstract][Full Text] [Related]
6. Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study.
Choi S; Seo S; Lee JH; Suh KJ; Kim JW; Kim JW; Kim SH; Kim YJ; Lee KW; Kim JH; Kim TW; Hong YS; Kim SY; Kim JE; Kim SW; Lee DH; Lee JC; Choi CM; Yoon S; Koh SJ; Min YJ; Ahn Y; Kim HJ; Baek JH; Park SR; Kim JH
Cancer Res Treat; 2024 Apr; 56(2):404-413. PubMed ID: 37933112
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials.
Zhao L; Li W; Zhang H; Hou N; Guo L; Gao Q
Onco Targets Ther; 2015; 8():2775-81. PubMed ID: 26491352
[TBL] [Abstract][Full Text] [Related]
8. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
9. Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis.
Tang N; Guo J; Zhang Q; Wang Y; Wang Z
Oncotarget; 2016 Jan; 7(3):3635-44. PubMed ID: 26498354
[TBL] [Abstract][Full Text] [Related]
10. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
Michelsen L; Sørensen JB
Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR.
Choi YJ; Lee DH; Choi CM; Lee JS; Lee SJ; Ahn JH; Kim SW
BMC Cancer; 2015 Oct; 15():763. PubMed ID: 26493267
[TBL] [Abstract][Full Text] [Related]
12. Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review.
Chen D; Zhang Y; Shi F; Li M; Zhu H; Kong L; Yu J
Onco Targets Ther; 2015; 8():2767-70. PubMed ID: 26491350
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.
Cesca M; Morosi L; Berndt A; Fuso Nerini I; Frapolli R; Richter P; Decio A; Dirsch O; Micotti E; Giordano S; D'Incalci M; Davoli E; Zucchetti M; Giavazzi R
Mol Cancer Ther; 2016 Jan; 15(1):125-35. PubMed ID: 26494857
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.
Hagman H; Frödin JE; Berglund Å; Sundberg J; Vestermark LW; Albertsson M; Fernebro E; Johnsson A
Ann Oncol; 2016 Jan; 27(1):140-7. PubMed ID: 26483047
[TBL] [Abstract][Full Text] [Related]
15. Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer.
Mahner S; Woelber L; Mueller V; Witzel I; Prieske K; Grimm D; Keller-V Amsberg G; Trillsch F
Front Oncol; 2015; 5():211. PubMed ID: 26500886
[TBL] [Abstract][Full Text] [Related]
16. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study).
Takeuchi K; Togashi Y; Kamihara Y; Fukuyama T; Yoshioka H; Inoue A; Katsuki H; Kiura K; Nakagawa K; Seto T; Maemondo M; Hida T; Harada M; Ohe Y; Nogami N; Yamamoto N; Nishio M; Tamura T
Ann Oncol; 2016 Jan; 27(1):185-92. PubMed ID: 26487585
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.
Munemoto Y; Kanda M; Ishibashi K; Hata T; Kobayashi M; Hasegawa J; Fukunaga M; Takagane A; Otsuji T; Miyake Y; Nagase M; Sakamoto J; Matsuoka M; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():786. PubMed ID: 26497654
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
Ilie M; Long-Mira E; Bence C; Butori C; Lassalle S; Bouhlel L; Fazzalari L; Zahaf K; Lalvée S; Washetine K; Mouroux J; Vénissac N; Poudenx M; Otto J; Sabourin JC; Marquette CH; Hofman V; Hofman P
Ann Oncol; 2016 Jan; 27(1):147-53. PubMed ID: 26483045
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.
Glynne-Jones R; Hava N; Goh V; Bosompem S; Bridgewater J; Chau I; Gaya A; Wasan H; Moran B; Melcher L; MacDonald A; Osborne M; Beare S; Jitlal M; Lopes A; Hall M; West N; Quirke P; Wong WL; Harrison M;
BMC Cancer; 2015 Oct; 15():764. PubMed ID: 26493588
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer.
Lantermann AB; Chen D; McCutcheon K; Hoffman G; Frias E; Ruddy D; Rakiec D; Korn J; McAllister G; Stegmeier F; Meyer MJ; Sharma SV
Cancer Res; 2015 Nov; 75(22):4937-48. PubMed ID: 26490646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
